Previous 10 | Next 10 |
Breathe Biologics Inc., a Pulmonary Regenerative Medicine Subsidiary of TSOI, Discloses Allogeneic Pulmonary Myeloid Suppressor Cell Based Product Therapeutic Solutions International (TSOI) announced today new data, licensing, and patent filing on a novel cellular therapy fo...
Phase III Clinical Trial Stem Cell Company Aims to Fast Forward Regenerative Solutions to Dreaded Lung Disease Therapeutic Solutions International (TSOI) announced today the launching of a spin-off company, Breathe Biologics, Inc., to commercialize technologies in the area o...
Company to Develop StemVacs-V Anti-Angiogenesis Immunotherapy for Initial Treatment of Breast Cancer Therapeutic Solutions International (TSOI) announced today formation of a Spin-Off Company, Res Nova Bio, Inc., dedicated to the development of cancer inhibiting anti-angioge...
Commercially Available Nutraceutical Potentially Effective Against COVID-19 Brain Fog Therapeutic Solutions International (TSOI) announced today receipt of a “Notice of Allowance” from the United States Patent and Trademark Office for its patent entitled ȁ...
Clinical Stage Stem Cell Company Leverages Knowledge Gained from Cancer Dendritic Cell Therapy StemVacs to Open New Door for COPD and ARDS Research Therapeutic Solutions International (TSOI) announced today new data suggesting that therapeutic effects of its universal donor ...
Company Announces $10,000,000 Common Stock Purchase Agreement with GHS Investments, LLC. Therapeutic Solutions International (TSOI), a clinical stage regenerative medicine and immunotherapy company, announced today it has entered into an agreement with GHS Investments, LLC (...
Validation of Efficacy for Second Suicide-Associated Psychiatric Indication Supports Push for Clinical Entry of Novel Brain-Healing Stem Cell Type Therapeutic Solutions International announced positive data and filing of a patent covering the use of CampbellCell for treatmen...
Phase III COVID-19 ARDS Company Continues Quest to Cure COPD Through Developing Clinically Applicable Solutions Therapeutic Solutions International announced today data and patent filing on a new approach to treating chronic obstructive pulmonary disease (COPD). The Comp...
Therapeutic Solutions ( OTCPK:TSOI ) announced on Monday data and filing of a patent covering the use of "gene silencing" to treat Acute Respiratory Distress Syndrome ( ARDS ). The Company currently is running a Phase III trial treating COVID-19 induced ARDS andhas request...
Company Continues Accelerated Development of Candidate Pipeline and Patent Portfolio in Respiratory Medicine Space as Phase III Trial Proceeds Therapeutic Solutions International announced today data and filing of a patent covering the use of “gene silencing” i...
News, Short Squeeze, Breakout and More Instantly...
Therapeutic Sltns Intl Company Name:
TSOI Stock Symbol:
OTCMKTS Market:
Therapeutic Sltns Intl Website:
Clinical Stage Stem Cell Company Granted Exclusivity on the Use of Specific Immune System Cells to Increase Efficacy of Stem Cells in Lung Inflammation Therapeutic Solutions International, Inc. (TSOI) announced today receipt of a Notice of Allowance from the United States Patent and Tra...
Therapeutic Solutions International Pre-Spin-Off Company Plans to Enter Capital Markets Through Partial Distribution of its Shares to Shareholders of Parent Company Therapeutic Solutions International, Inc. (TSOI) Pre-Spin-Off Company Plans to Enter Capital Markets Through Partial Distr...
Latest Patent to Complement Issued Claims on Viral Inhibition, Adaptive Immune Stimulation, and Brain Protection/Regeneration Therapeutic Solutions International, Inc. (TSOI), a clinical-stage stem cell and immunotherapy company, announced today the granting of a patent covering the abi...